Results 291 to 300 of about 488,286 (382)

Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and
Jing Zhang, Huixia Zhang, Yajuan Zhang, Shuyuan Liu, Xiaoyun Ge, Haiyue Zhang, Yunfei Li, Cecil Chi‐Keung Chen, Oleg Stepanov, Weifeng Tang, Wenhong Zhang   +10 more
wiley   +1 more source

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This 2‐part, randomized, placebo‐controlled, double‐blind, Phase 1 study analyzed the pharmacokinetics, safety, and biomarker profile of fezolinetant in healthy Japanese individuals. Part 1: male participants received single doses of placebo or fezolinetant 15 or 60 mg.
Akira Koibuchi, Megumi Iwai, Kanji Komatsu, Kentaro Kuroishi, Mai Shibata, Masako Saito, Jace Nielsen, Jiayin Huang, Shunji Matsuki   +8 more
wiley   +1 more source

Effects of Open-Label Placebos on Visual Food Cue Reactivity in Children and Adolescents. [PDF]

Children (Basel)
Schienle A, Polz A, Haslacher K, Osmani F, Kogler W.   +4 more
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, in Healthy Chinese Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Galcanezumab is used in several regions, including the United States, Europe, and China, as a preventive treatment for migraine. This study aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of galcanezumab in healthy Chinese participants.
Jingjing Wang, Nanyang Li, Jinjie He, Jing Zhang, Lili Wang, William Kielbasa, Chenxi Qian, Yanjie Zhang, Liang Wang   +8 more
wiley   +1 more source

Placebo Effects: Neurological Mechanisms Inducing Physiological, Organic, and Belief Responses-A Prospective Analysis. [PDF]

Healthcare (Basel)
Niazi SK.
europepmc   +1 more source

Placebo

Forum Médical Suisse ‒ Swiss Medical Forum, 2007
openaire   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Safety of creatine supplementation: analysis of the prevalence of reported side effects in clinical trials and adverse event reports. [PDF]

J Int Soc Sports Nutr
Kreider RB, Gonzalez DE, Hines K, Gil A, Bonilla DA.   +4 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Medication Administration in Poststroke Dysphagia: Evaluating Swallowing Safety of Solid Dosage Forms. [PDF]

Stroke
Trapl-Grundschober M, Struhal W, Teuschl Y, Schulz S, Sollereder S, Osterbrink J.   +5 more
europepmc   +1 more source